Semaglutide. Tirzepatide. Liraglutide. Whatever brand name your friend, your spouse, or your patient is on, the GLP-1 receptor agonist class is now the default first-line tool for weight loss in a way nothing has been since statins entered cardiology. And every clinician we work with is hearing the same three sentences in their patient intake:
"It's working — but I'm constipated all the time. I have nausea every morning. I think I might have SIBO."
None of those are bugs. They are the predictable consequence of how the drug works. GLP-1 agonists slow gastric emptying — that is the mechanism that produces satiety and the lower caloric intake. Slower transit means food sits longer in the stomach, then longer in the small intestine, then longer in the colon. Each of those time changes does something different to your microbiome. Most of it is not bad. Some of it is unhelpful. And almost none of it is being managed by the people designing the GLP-1 prescription.
What actually changes in your gut on a GLP-1
Three shifts are well-documented in the first 12 weeks:
- Gastric emptying slows 30–70%. Food, water, and any oral medications spend much longer in the stomach. Fermentable carbohydrates that would normally pass through unchallenged now sit in a warm acidic pool — a small but real opportunity for upper-GI bacterial overgrowth (the "SIBO-like" symptoms most patients report).
- Bile acid signaling shifts. Lower food intake means less cholecystokinin and less bile release. Your gut's bile-acid-deconjugating strains (mostly Lactobacillus and Bifidobacterium species with bile salt hydrolase activity) get less work — and their populations drop accordingly.
- Colonic transit slows, often by 50%. Less stool bulk, less hydration pulled forward, and more time for water reabsorption in the colon. That is the constipation everyone is reporting. It is also a setup for dysbiosis-driven gas and bloating, because slow transit means more methane producers can outcompete hydrogen producers.
None of this is dangerous on its own. But all of it is uncomfortable enough that a meaningful percentage of patients quit GLP-1 in the first 90 days — and the GI side effects are the #1 reason cited. That is a strain-specific problem with a strain-specific solution.
The strains that actually help on a GLP-1
Most off-the-shelf "for weight loss" probiotics are useless here. They are usually high-CFU bacteroidetes-heavy blends marketed on the firmicutes-to-bacteroidetes-ratio story, which has not replicated in the literature for almost a decade. What you actually want on a GLP-1 is a small, surgical set of strains that address each of the three shifts above:
- For slow gastric emptying: Bifidobacterium lactis HN019 has the strongest human-trial evidence for accelerating gastric and whole-gut transit time. A 14-day course can shave 12–24 hours off mean transit. That is the mechanism that prevents the upper-GI fermentation that produces the "I think I have SIBO" sensation.
- For bile acid recycling: Lactobacillus plantarum (specifically strains with bile salt hydrolase, like LP299v) supports bile acid deconjugation. Less raw bile in circulation, more useful secondary bile acids reaching the colon — and a quieter gut-brain inflammation signal.
- For constipation and colonic transit: Bifidobacterium animalis and Lactobacillus rhamnosus — the most boring entries in any probiotic — are also the two with the most consistent constipation-relief literature when given at 4–6B CFU.
What you do not want, on a GLP-1, is the giant 100-billion-CFU blunderbuss product that's everywhere. With slowed transit you're now keeping strains in your upper GI much longer than they're supposed to be. High dose plus high residence time is the recipe for histamine flares (Lactobacillus casei, L. bulgaricus) and SIBO worsening. More on that here.
What to actually do
If you are on a GLP-1 or starting one, treat your gut like a second variable to dose. The drug is variable one. The food intake change is variable two. Your microbiome is variable three. Strain-specific support — five strains, in the 20–35B CFU range, paired with a fermentable fiber prebiotic — does more for the side-effect profile than 90% of the "drink more water" advice circulating online.
If you have a microbiome test already, look at three things: your Bifidobacterium total fraction (should be above 3%), your Akkermansia muciniphila presence (any detectable is good news for GLP-1 patients — it co-regulates GLP-1 endogenously), and your archaeal methane producers (high Methanobrevibacter smithii predicts worse constipation on a GLP-1 and is worth flagging to your prescriber).
None of this requires you to stop or pause the drug. It requires you to stop treating "GLP-1 side effects" as a black box and start treating them as three predictable, addressable shifts. That is what a strain-specific probiotic strategy looks like — and it is the kind of intervention that becomes obvious once you stop thinking about probiotics as a CFU number on a bottle.
Want a probiotic tuned to your ecosystem, not a CFU number?
Flore builds personalized 5-strain Precision blends from your microbiome data.
Shop Flore →